Table 4 Baseline clinical data of patients enrolled in the REAL study
From: The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil
Clinical Data | Absolute value or % | n |
|---|---|---|
Disease duration, years, median (range) | 12.7 (0.7–56.9) | 1114 |
Time from symptoms to diagnosis, months, median (range) | 12 (1–457) | 1078 |
Time from symptoms to 1st DMARD, months, median (range) | 12 (1–624) | 994 |
Patients with ≥1 extra-articular manifestation, % | 23.3 | 1115 |
Positive rheumatoid factor, % | 78.2 | 1105 |
Positive anti-citrullinated peptide antibody, % | 77.2 | 477 |
Erosive disease, % | 54.9 | 1095 |
Patients fulfilling classification criteria, %: | ||
ARA 1987 | 90.0 | 1115 |
ACR/EULAR 2010 | 90.9 | 1115 |
Both | 80.8 | 1115 |
Drugs in use, %: | ||
Glucocorticoids | 47.4 | 1115 |
Nonsteroidal anti-inflammatory drugs | 9.1 | 1115 |
Synthetic DMARD | 90.9 | 1115 |
Methotrexate | 66.5 | 1115 |
Biologic DMARD | 35.7 | 1115 |
Biologic DMARD in monotherapy | 5,6 | 1115 |
ESR, median (range) | 21 (1–140) | 923 |
CRP median (range) | 0.7 (0–76.1) | 944 |
Pain (VAS 0–100), median (range) | 40 (0–100) | 1115 |
Fatigue (VAS 0–100), median (range) | 40 (0–100) | 1115 |
Global health assessment (VAS 0–100), median (range) | 38 (0–100) | 1115 |
DAS28-ESR, median (range) | 3.5 (0.3–8.2) | 923 |
Remission | 26.2 | |
Low disease activity | 15.1 | |
Moderate disease activity | 41.8 | |
High disease activity | 16.9 | |
CDAI, median (range) | 9 (0–70) | 1113 |
Remission | 20.1 | |
Low disease activity | 33.2 | |
Moderate disease activity | 27.5 | |
High disease activity | 19.2 | |
HAQ-DI, median (range) | 0.875 (0–3) | 1111 |
SF-12 physical, median (range) | 36.1 (17.5–55.9) | 1079 |
SF-12 mental, median (range) | 47.1 (14.3–72.0) | 1079 |